NCT05828381View on ClinicalTrials.gov

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Immunotherapy;Envafolimab; Esophageal Cancer
Interventions
DRUG

Envafolimab

300mg,sc,d1,q3w; for a total of 2 cycles.

DRUG

Abraxane

100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles

DRUG

Cisplatin

75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles

All Listed Sponsors
lead

Fujian Medical University Union Hospital

OTHER

NCT05828381 - Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer | Biotech Hunter | Biotech Hunter